IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: I. Luttichuys who wrote (439)	3/7/1997 6:14:00 PM
From: Brad C. Dunlap	of 1762

Once again Eric Hecht[are potential big gun] better get moving. This report from Montgomery reads great. I was not aware that current manufacturing is being run 24 hours a day in order to build inventories to meet commercial demand at launch. The analyst also states that C2B8 is exactly what type of product the FDA had in mind when they developed the new anti- cancer guidlines. Another reason why Scott Sacane[analyst] believes the FDA process will proceed quickly is that the FDA personnel and oncology leaders were members of the committee that developed the outcome criteria for C2B8 clinical trials. These people in fact co-authored publications describing the criteria and we expect that this familiarity and agreement with the criteria will serve to speed the product through the FDA advisory committee and internal regulatory review. Finally, this stock would be at 28 if it wasn't for the Market maker[Smith Barny] whom I suspect is selling for SmithKline Beecham. They probably sold at least 500,000 shares this past week. Should be an exciting future.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next